Sjögren's Syndrome

Sjögren's syndrome is an autoimmune disease affecting approximately 0.5-1% of people worldwide, with women accounting for about 90% of cases. The immune system mistakenly attacks the body's moisture-producing glands, particularly the tear and saliva glands, leading to the hallmark symptoms of dry eyes and dry mouth. This happens when certain immune cells (B cells and T cells) infiltrate these glands, causing inflammation and progressive damage. The condition can occur on its own (primary Sjögren's) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary Sjögren's). Beyond dryness, many people experience systemic symptoms including profound fatigue, joint pain, and sometimes involvement of other organs like the lungs, kidneys, or nervous system. The underlying cause isn't fully understood, but appears to involve a combination of genetic susceptibility and environmental triggers that set off the autoimmune response. Diagnosis can be challenging since symptoms develop gradually and overlap with many other conditions.

Treatment currently focuses on managing symptoms and complications. For dry eyes, artificial tears and lubricating eye drops provide relief, with prescription anti-inflammatory eye drops (cyclosporine, lifitegrast) used for more severe cases. Dry mouth is managed with saliva substitutes, frequent water sipping, sugar-free gum, and medications like pilocarpine or cevimeline that stimulate remaining gland function. Good dental care is essential to prevent cavities and gum disease that dry mouth can cause. For people with joint pain or systemic symptoms, doctors may prescribe hydroxychloroquine, which helps with fatigue and joint problems in some patients. When internal organs are affected or symptoms are severe, immunosuppressive medications like methotrexate or corticosteroids may be used, though these come with significant side effects. Lifestyle modifications including humidifiers, protective eyewear, and staying well-hydrated help manage daily symptoms. Physical therapy and exercise programs can improve energy levels and joint function. While these approaches help people manage symptoms and maintain quality of life, they don't address the underlying immune dysfunction driving the disease.

The absence of approved disease-modifying therapies that target the underlying autoimmune process represents the primary treatment gap. Current symptom management, while helpful, doesn't prevent progressive gland damage or address the root immune dysfunction. Profound fatigue affects most people with Sjögren's and often proves more disabling than dryness, yet remains poorly understood and difficult to treat with available options. Systemic manifestations—including lung inflammation, kidney problems, nerve damage, and cognitive difficulties—require better treatment approaches. The unpredictable nature of the disease, with some people experiencing primarily glandness while others develop serious organ involvement, makes it difficult to know who needs more aggressive treatment. Sjögren's also carries an increased risk of lymphoma compared to the general population, creating need for better monitoring strategies and preventive approaches. Early diagnosis remains challenging because symptoms develop slowly and can mimic other conditions, meaning people often experience symptoms for years before receiving the correct diagnosis and appropriate care.

Several targeted biologic therapies are in Phase 2 and Phase 3 trials, focusing on specific immune pathways involved in Sjögren's. Ianalumab, an antibody that depletes B cells through a different mechanism than earlier approaches, has shown promising results in Phase 2 trials for improving dryness symptoms and reducing disease activity markers. Iscalimab, which blocks a protein called CD40 involved in immune cell communication, demonstrated improvements in symptoms and objective measures of gland function in mid-stage trials. Nipocalimab, designed to reduce harmful antibodies by targeting a specific receptor, is being evaluated for its effects on systemic manifestations. Researchers are testing medications that block BAFF (B-cell activating factor), a protein that promotes survival of the problematic immune cells, with several compounds in development. Repurposed drugs including low-dose naltrexone and metformin are being studied in smaller trials based on their anti-inflammatory and metabolic effects. Researchers have learned from earlier trial setbacks—particularly with rituximab, which showed mixed results—and are now using better outcome measures and selecting patients more carefully to increase the chances of demonstrating meaningful benefit.

CAR-T cell therapy, which has revolutionized cancer treatment, is being explored as a way to precisely eliminate the specific immune cells causing Sjögren's while leaving the rest of the immune system intact. Scientists are investigating regenerative medicine approaches to restore function to damaged salivary and tear glands, including methods to stimulate remaining gland cells to multiply or differentiate stem cells into new gland tissue. Novel biologics targeting newly discovered immune pathways, including specific cytokines and cellular checkpoints involved in Sjögren's, are in early development. Researchers are working to identify biomarkers in blood, saliva, or tears that could enable earlier diagnosis, predict who will develop severe disease, and track treatment response more accurately than current clinical measures. Small molecule drugs that can be taken orally rather than infused are being designed to block key inflammatory signals. Microbiome research is investigating whether alterations in oral or gut bacteria contribute to disease and whether modifying these bacterial communities could provide therapeutic benefit. Gene therapy approaches to correct immune dysregulation and tolerance-inducing therapies to re-educate the immune system are being studied in animal models.

Sjögren's syndrome is an autoimmune disease affecting approximately 0.5-1% of people worldwide, with women accounting for about 90% of cases. The immune system mistakenly attacks the body's moisture-producing glands, particularly the tear and saliva glands, leading to the hallmark symptoms of dry eyes and dry mouth. This happens when certain immune cells (B cells and T cells) infiltrate these glands, causing inflammation and progressive damage. The condition can occur on its own (primary Sjögren's) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary Sjögren's). Beyond dryness, many people experience systemic symptoms including profound fatigue, joint pain, and sometimes involvement of other organs like the lungs, kidneys, or nervous system. The underlying cause isn't fully understood, but appears to involve a combination of genetic susceptibility and environmental triggers that set off the autoimmune response. Diagnosis can be challenging since symptoms develop gradually and overlap with many other conditions.

Treatment currently focuses on managing symptoms and complications. For dry eyes, artificial tears and lubricating eye drops provide relief, with prescription anti-inflammatory eye drops (cyclosporine, lifitegrast) used for more severe cases. Dry mouth is managed with saliva substitutes, frequent water sipping, sugar-free gum, and medications like pilocarpine or cevimeline that stimulate remaining gland function. Good dental care is essential to prevent cavities and gum disease that dry mouth can cause. For people with joint pain or systemic symptoms, doctors may prescribe hydroxychloroquine, which helps with fatigue and joint problems in some patients. When internal organs are affected or symptoms are severe, immunosuppressive medications like methotrexate or corticosteroids may be used, though these come with significant side effects. Lifestyle modifications including humidifiers, protective eyewear, and staying well-hydrated help manage daily symptoms. Physical therapy and exercise programs can improve energy levels and joint function. While these approaches help people manage symptoms and maintain quality of life, they don't address the underlying immune dysfunction driving the disease.

The absence of approved disease-modifying therapies that target the underlying autoimmune process represents the primary treatment gap. Current symptom management, while helpful, doesn't prevent progressive gland damage or address the root immune dysfunction. Profound fatigue affects most people with Sjögren's and often proves more disabling than dryness, yet remains poorly understood and difficult to treat with available options. Systemic manifestations—including lung inflammation, kidney problems, nerve damage, and cognitive difficulties—require better treatment approaches. The unpredictable nature of the disease, with some people experiencing primarily glandness while others develop serious organ involvement, makes it difficult to know who needs more aggressive treatment. Sjögren's also carries an increased risk of lymphoma compared to the general population, creating need for better monitoring strategies and preventive approaches. Early diagnosis remains challenging because symptoms develop slowly and can mimic other conditions, meaning people often experience symptoms for years before receiving the correct diagnosis and appropriate care.

Several targeted biologic therapies are in Phase 2 and Phase 3 trials, focusing on specific immune pathways involved in Sjögren's. Ianalumab, an antibody that depletes B cells through a different mechanism than earlier approaches, has shown promising results in Phase 2 trials for improving dryness symptoms and reducing disease activity markers. Iscalimab, which blocks a protein called CD40 involved in immune cell communication, demonstrated improvements in symptoms and objective measures of gland function in mid-stage trials. Nipocalimab, designed to reduce harmful antibodies by targeting a specific receptor, is being evaluated for its effects on systemic manifestations. Researchers are testing medications that block BAFF (B-cell activating factor), a protein that promotes survival of the problematic immune cells, with several compounds in development. Repurposed drugs including low-dose naltrexone and metformin are being studied in smaller trials based on their anti-inflammatory and metabolic effects. Researchers have learned from earlier trial setbacks—particularly with rituximab, which showed mixed results—and are now using better outcome measures and selecting patients more carefully to increase the chances of demonstrating meaningful benefit.

CAR-T cell therapy, which has revolutionized cancer treatment, is being explored as a way to precisely eliminate the specific immune cells causing Sjögren's while leaving the rest of the immune system intact. Scientists are investigating regenerative medicine approaches to restore function to damaged salivary and tear glands, including methods to stimulate remaining gland cells to multiply or differentiate stem cells into new gland tissue. Novel biologics targeting newly discovered immune pathways, including specific cytokines and cellular checkpoints involved in Sjögren's, are in early development. Researchers are working to identify biomarkers in blood, saliva, or tears that could enable earlier diagnosis, predict who will develop severe disease, and track treatment response more accurately than current clinical measures. Small molecule drugs that can be taken orally rather than infused are being designed to block key inflammatory signals. Microbiome research is investigating whether alterations in oral or gut bacteria contribute to disease and whether modifying these bacterial communities could provide therapeutic benefit. Gene therapy approaches to correct immune dysregulation and tolerance-inducing therapies to re-educate the immune system are being studied in animal models.

Sjögren's syndrome is an autoimmune disease affecting approximately 0.5-1% of people worldwide, with women accounting for about 90% of cases. The immune system mistakenly attacks the body's moisture-producing glands, particularly the tear and saliva glands, leading to the hallmark symptoms of dry eyes and dry mouth. This happens when certain immune cells (B cells and T cells) infiltrate these glands, causing inflammation and progressive damage. The condition can occur on its own (primary Sjögren's) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary Sjögren's). Beyond dryness, many people experience systemic symptoms including profound fatigue, joint pain, and sometimes involvement of other organs like the lungs, kidneys, or nervous system. The underlying cause isn't fully understood, but appears to involve a combination of genetic susceptibility and environmental triggers that set off the autoimmune response. Diagnosis can be challenging since symptoms develop gradually and overlap with many other conditions.

Treatment currently focuses on managing symptoms and complications. For dry eyes, artificial tears and lubricating eye drops provide relief, with prescription anti-inflammatory eye drops (cyclosporine, lifitegrast) used for more severe cases. Dry mouth is managed with saliva substitutes, frequent water sipping, sugar-free gum, and medications like pilocarpine or cevimeline that stimulate remaining gland function. Good dental care is essential to prevent cavities and gum disease that dry mouth can cause. For people with joint pain or systemic symptoms, doctors may prescribe hydroxychloroquine, which helps with fatigue and joint problems in some patients. When internal organs are affected or symptoms are severe, immunosuppressive medications like methotrexate or corticosteroids may be used, though these come with significant side effects. Lifestyle modifications including humidifiers, protective eyewear, and staying well-hydrated help manage daily symptoms. Physical therapy and exercise programs can improve energy levels and joint function. While these approaches help people manage symptoms and maintain quality of life, they don't address the underlying immune dysfunction driving the disease.

The absence of approved disease-modifying therapies that target the underlying autoimmune process represents the primary treatment gap. Current symptom management, while helpful, doesn't prevent progressive gland damage or address the root immune dysfunction. Profound fatigue affects most people with Sjögren's and often proves more disabling than dryness, yet remains poorly understood and difficult to treat with available options. Systemic manifestations—including lung inflammation, kidney problems, nerve damage, and cognitive difficulties—require better treatment approaches. The unpredictable nature of the disease, with some people experiencing primarily glandness while others develop serious organ involvement, makes it difficult to know who needs more aggressive treatment. Sjögren's also carries an increased risk of lymphoma compared to the general population, creating need for better monitoring strategies and preventive approaches. Early diagnosis remains challenging because symptoms develop slowly and can mimic other conditions, meaning people often experience symptoms for years before receiving the correct diagnosis and appropriate care.

Several targeted biologic therapies are in Phase 2 and Phase 3 trials, focusing on specific immune pathways involved in Sjögren's. Ianalumab, an antibody that depletes B cells through a different mechanism than earlier approaches, has shown promising results in Phase 2 trials for improving dryness symptoms and reducing disease activity markers. Iscalimab, which blocks a protein called CD40 involved in immune cell communication, demonstrated improvements in symptoms and objective measures of gland function in mid-stage trials. Nipocalimab, designed to reduce harmful antibodies by targeting a specific receptor, is being evaluated for its effects on systemic manifestations. Researchers are testing medications that block BAFF (B-cell activating factor), a protein that promotes survival of the problematic immune cells, with several compounds in development. Repurposed drugs including low-dose naltrexone and metformin are being studied in smaller trials based on their anti-inflammatory and metabolic effects. Researchers have learned from earlier trial setbacks—particularly with rituximab, which showed mixed results—and are now using better outcome measures and selecting patients more carefully to increase the chances of demonstrating meaningful benefit.

CAR-T cell therapy, which has revolutionized cancer treatment, is being explored as a way to precisely eliminate the specific immune cells causing Sjögren's while leaving the rest of the immune system intact. Scientists are investigating regenerative medicine approaches to restore function to damaged salivary and tear glands, including methods to stimulate remaining gland cells to multiply or differentiate stem cells into new gland tissue. Novel biologics targeting newly discovered immune pathways, including specific cytokines and cellular checkpoints involved in Sjögren's, are in early development. Researchers are working to identify biomarkers in blood, saliva, or tears that could enable earlier diagnosis, predict who will develop severe disease, and track treatment response more accurately than current clinical measures. Small molecule drugs that can be taken orally rather than infused are being designed to block key inflammatory signals. Microbiome research is investigating whether alterations in oral or gut bacteria contribute to disease and whether modifying these bacterial communities could provide therapeutic benefit. Gene therapy approaches to correct immune dysregulation and tolerance-inducing therapies to re-educate the immune system are being studied in animal models.

Sjögren's syndrome is an autoimmune disease affecting approximately 0.5-1% of people worldwide, with women accounting for about 90% of cases. The immune system mistakenly attacks the body's moisture-producing glands, particularly the tear and saliva glands, leading to the hallmark symptoms of dry eyes and dry mouth. This happens when certain immune cells (B cells and T cells) infiltrate these glands, causing inflammation and progressive damage. The condition can occur on its own (primary Sjögren's) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary Sjögren's). Beyond dryness, many people experience systemic symptoms including profound fatigue, joint pain, and sometimes involvement of other organs like the lungs, kidneys, or nervous system. The underlying cause isn't fully understood, but appears to involve a combination of genetic susceptibility and environmental triggers that set off the autoimmune response. Diagnosis can be challenging since symptoms develop gradually and overlap with many other conditions.

Treatment currently focuses on managing symptoms and complications. For dry eyes, artificial tears and lubricating eye drops provide relief, with prescription anti-inflammatory eye drops (cyclosporine, lifitegrast) used for more severe cases. Dry mouth is managed with saliva substitutes, frequent water sipping, sugar-free gum, and medications like pilocarpine or cevimeline that stimulate remaining gland function. Good dental care is essential to prevent cavities and gum disease that dry mouth can cause. For people with joint pain or systemic symptoms, doctors may prescribe hydroxychloroquine, which helps with fatigue and joint problems in some patients. When internal organs are affected or symptoms are severe, immunosuppressive medications like methotrexate or corticosteroids may be used, though these come with significant side effects. Lifestyle modifications including humidifiers, protective eyewear, and staying well-hydrated help manage daily symptoms. Physical therapy and exercise programs can improve energy levels and joint function. While these approaches help people manage symptoms and maintain quality of life, they don't address the underlying immune dysfunction driving the disease.

The absence of approved disease-modifying therapies that target the underlying autoimmune process represents the primary treatment gap. Current symptom management, while helpful, doesn't prevent progressive gland damage or address the root immune dysfunction. Profound fatigue affects most people with Sjögren's and often proves more disabling than dryness, yet remains poorly understood and difficult to treat with available options. Systemic manifestations—including lung inflammation, kidney problems, nerve damage, and cognitive difficulties—require better treatment approaches. The unpredictable nature of the disease, with some people experiencing primarily glandness while others develop serious organ involvement, makes it difficult to know who needs more aggressive treatment. Sjögren's also carries an increased risk of lymphoma compared to the general population, creating need for better monitoring strategies and preventive approaches. Early diagnosis remains challenging because symptoms develop slowly and can mimic other conditions, meaning people often experience symptoms for years before receiving the correct diagnosis and appropriate care.

Several targeted biologic therapies are in Phase 2 and Phase 3 trials, focusing on specific immune pathways involved in Sjögren's. Ianalumab, an antibody that depletes B cells through a different mechanism than earlier approaches, has shown promising results in Phase 2 trials for improving dryness symptoms and reducing disease activity markers. Iscalimab, which blocks a protein called CD40 involved in immune cell communication, demonstrated improvements in symptoms and objective measures of gland function in mid-stage trials. Nipocalimab, designed to reduce harmful antibodies by targeting a specific receptor, is being evaluated for its effects on systemic manifestations. Researchers are testing medications that block BAFF (B-cell activating factor), a protein that promotes survival of the problematic immune cells, with several compounds in development. Repurposed drugs including low-dose naltrexone and metformin are being studied in smaller trials based on their anti-inflammatory and metabolic effects. Researchers have learned from earlier trial setbacks—particularly with rituximab, which showed mixed results—and are now using better outcome measures and selecting patients more carefully to increase the chances of demonstrating meaningful benefit.

CAR-T cell therapy, which has revolutionized cancer treatment, is being explored as a way to precisely eliminate the specific immune cells causing Sjögren's while leaving the rest of the immune system intact. Scientists are investigating regenerative medicine approaches to restore function to damaged salivary and tear glands, including methods to stimulate remaining gland cells to multiply or differentiate stem cells into new gland tissue. Novel biologics targeting newly discovered immune pathways, including specific cytokines and cellular checkpoints involved in Sjögren's, are in early development. Researchers are working to identify biomarkers in blood, saliva, or tears that could enable earlier diagnosis, predict who will develop severe disease, and track treatment response more accurately than current clinical measures. Small molecule drugs that can be taken orally rather than infused are being designed to block key inflammatory signals. Microbiome research is investigating whether alterations in oral or gut bacteria contribute to disease and whether modifying these bacterial communities could provide therapeutic benefit. Gene therapy approaches to correct immune dysregulation and tolerance-inducing therapies to re-educate the immune system are being studied in animal models.

Sjögren's syndrome is an autoimmune disease affecting approximately 0.5-1% of people worldwide, with women accounting for about 90% of cases. The immune system mistakenly attacks the body's moisture-producing glands, particularly the tear and saliva glands, leading to the hallmark symptoms of dry eyes and dry mouth. This happens when certain immune cells (B cells and T cells) infiltrate these glands, causing inflammation and progressive damage. The condition can occur on its own (primary Sjögren's) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary Sjögren's). Beyond dryness, many people experience systemic symptoms including profound fatigue, joint pain, and sometimes involvement of other organs like the lungs, kidneys, or nervous system. The underlying cause isn't fully understood, but appears to involve a combination of genetic susceptibility and environmental triggers that set off the autoimmune response. Diagnosis can be challenging since symptoms develop gradually and overlap with many other conditions.

Treatment currently focuses on managing symptoms and complications. For dry eyes, artificial tears and lubricating eye drops provide relief, with prescription anti-inflammatory eye drops (cyclosporine, lifitegrast) used for more severe cases. Dry mouth is managed with saliva substitutes, frequent water sipping, sugar-free gum, and medications like pilocarpine or cevimeline that stimulate remaining gland function. Good dental care is essential to prevent cavities and gum disease that dry mouth can cause. For people with joint pain or systemic symptoms, doctors may prescribe hydroxychloroquine, which helps with fatigue and joint problems in some patients. When internal organs are affected or symptoms are severe, immunosuppressive medications like methotrexate or corticosteroids may be used, though these come with significant side effects. Lifestyle modifications including humidifiers, protective eyewear, and staying well-hydrated help manage daily symptoms. Physical therapy and exercise programs can improve energy levels and joint function. While these approaches help people manage symptoms and maintain quality of life, they don't address the underlying immune dysfunction driving the disease.

The absence of approved disease-modifying therapies that target the underlying autoimmune process represents the primary treatment gap. Current symptom management, while helpful, doesn't prevent progressive gland damage or address the root immune dysfunction. Profound fatigue affects most people with Sjögren's and often proves more disabling than dryness, yet remains poorly understood and difficult to treat with available options. Systemic manifestations—including lung inflammation, kidney problems, nerve damage, and cognitive difficulties—require better treatment approaches. The unpredictable nature of the disease, with some people experiencing primarily glandness while others develop serious organ involvement, makes it difficult to know who needs more aggressive treatment. Sjögren's also carries an increased risk of lymphoma compared to the general population, creating need for better monitoring strategies and preventive approaches. Early diagnosis remains challenging because symptoms develop slowly and can mimic other conditions, meaning people often experience symptoms for years before receiving the correct diagnosis and appropriate care.

Several targeted biologic therapies are in Phase 2 and Phase 3 trials, focusing on specific immune pathways involved in Sjögren's. Ianalumab, an antibody that depletes B cells through a different mechanism than earlier approaches, has shown promising results in Phase 2 trials for improving dryness symptoms and reducing disease activity markers. Iscalimab, which blocks a protein called CD40 involved in immune cell communication, demonstrated improvements in symptoms and objective measures of gland function in mid-stage trials. Nipocalimab, designed to reduce harmful antibodies by targeting a specific receptor, is being evaluated for its effects on systemic manifestations. Researchers are testing medications that block BAFF (B-cell activating factor), a protein that promotes survival of the problematic immune cells, with several compounds in development. Repurposed drugs including low-dose naltrexone and metformin are being studied in smaller trials based on their anti-inflammatory and metabolic effects. Researchers have learned from earlier trial setbacks—particularly with rituximab, which showed mixed results—and are now using better outcome measures and selecting patients more carefully to increase the chances of demonstrating meaningful benefit.

CAR-T cell therapy, which has revolutionized cancer treatment, is being explored as a way to precisely eliminate the specific immune cells causing Sjögren's while leaving the rest of the immune system intact. Scientists are investigating regenerative medicine approaches to restore function to damaged salivary and tear glands, including methods to stimulate remaining gland cells to multiply or differentiate stem cells into new gland tissue. Novel biologics targeting newly discovered immune pathways, including specific cytokines and cellular checkpoints involved in Sjögren's, are in early development. Researchers are working to identify biomarkers in blood, saliva, or tears that could enable earlier diagnosis, predict who will develop severe disease, and track treatment response more accurately than current clinical measures. Small molecule drugs that can be taken orally rather than infused are being designed to block key inflammatory signals. Microbiome research is investigating whether alterations in oral or gut bacteria contribute to disease and whether modifying these bacterial communities could provide therapeutic benefit. Gene therapy approaches to correct immune dysregulation and tolerance-inducing therapies to re-educate the immune system are being studied in animal models.